FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Please provide your email address to receive an email when new articles are posted on . In 2013, Malvina B. Eydelman, MD, director of the FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices, ...

Randomization (2:1:1) compared 78 mcg or 39 mcg BIM-IOL plus artificial tears versus standard monofocal IOL plus twice-daily timolol, with IOP change assessed at early visits. Mean IOP reduction at 12 ...

Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.

Please provide your email address to receive an email when new articles are posted on . Capsulorrhexis is an essential aspect of and a prerequisite for performing phacoemulsification surgery. Gimbel ...

Johnson & Johnson introduces the TECNIS Odyssey IOL in India, enhancing vision for cataract patients with advanced technology.

Celebrating 75 years of intraocular lens advancements that have improved care for millions of cataract patients. On November 29, 1949, Sir Harold Ridley performed a surgical procedure to replace a ...

Intraocular lens (IOL) design has continued to evolve since being introduced in 1949. We have seen an evolution not only in design, but also in material, optics, safety, and efficacy, among other ...